Back to Editor profile » Professor Israel (Rudi) Rubinstein

Professor Israel (Rudi) Rubinstein

Professor Israel (Rudi) Rubinstein

Editor-in-Chief: Dr Israel Rubinstein

Dr Israel Rubinstein is professor of medicine in the College of Medicine at the University of Illinois at Chicago. He is a member of the Section of Pulmonary, Critical Care, Allergy and Sleep Medicine at the Department of Medicine, University of Illinois at Chicago, and attending physician at the University of Illinois at Chicago Medical Center and Jesse Brown VA Medical Center, Chicago, Illinois, USA. Dr Rubinstein received his medical degree from the Hebrew University–Hadassah School of Medicine in Jerusalem. He was a medical resident in Israel, fellow in respirology at the University of Toronto and research fellow at the Cardiovascular Research Institute, University of California at San Francisco. He is board-certified in internal medicine and pulmonary disease. Dr Rubinstein holds 18 issued and pending US and international patents and has authored more than 190 peer-reviewed articles in scientific journals.

Dr Rubinstein’s research interests include nanomedicine, targeted drug delivery, and bioimaging. Dr Rubinstein is the Editor-in-Chief of the International Journal of Nanomedicine and associate editor of the Journal of Biomedical Nanotechnology and member of the editorial board of several scientific journals. He is a member of the Scientific Advisory Board of the International Academy of Cardiology. Dr Rubinstein is a fellow of the American Heart Association, American College of Physicians and American College of Chest Physicians. In addition, he is a member of the American Thoracic Society, American Physiological Society, American Society for Pharmacology and Experimental Therapeutics, American Microbiology Society and the Microcirculatory Society. He is a board member and director of Advanced Life Sciences, a publicly-traded biopharmaceutical company in Woodridge, Illinois, USA, engaged in the discovery, development and commercialization of drugs in the areas of infection, cancer and respiratory disease.   

Updated 14 October 2021